July 6, 2020 -- Anixa Biosciences and OntoChem have completed in silico screening of four compounds that could function as SARS-CoV-2 main protease inhibitors.
The companies previously announced that they identified four compounds that could disrupt the function of endoribonuclease (also known as nonstructural protein-15; NSP-15). These have been synthesized and are in the process of being tested in biological assays.
Now, the companies have jointly developed a new in silico library of analog compounds, based on the main protease scaffold compound, that will be evaluated through additional in silico screening to choose which additional compounds may be synthesized and evaluated in biological assays.
Complete screening results are expected to be available within weeks.